Welcome to our dedicated page for Oculis Holding SEC filings (Ticker: OCS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oculis Holding AG (OCS) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory submissions, primarily filed as a foreign private issuer on Form 20-F and Form 6-K. These documents provide detail on Oculis’ biopharmaceutical business in ophthalmology and neuro-ophthalmology, its late-stage clinical pipeline, and its financing arrangements.
Form 6-K reports referenced in public records include unaudited condensed consolidated interim financial statements and management’s discussion and analysis for half-year and quarterly periods. Other 6-K filings describe capital-raising transactions, such as underwritten and registered direct offerings of ordinary shares made under shelf registration statements on Form F-3, as well as the suspension of an at-the-market prospectus supplement. Additional filings outline an amended and restated loan facility with a lender affiliated with BlackRock, including warrant terms linked to borrowing tranches.
These filings also incorporate press releases and corporate presentations that discuss the advancement of Privosegtor into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy, the Phase 3 DIAMOND program for OCS-01 eye drops in diabetic macular edema, and development plans for Licaminlimab in dry eye disease. Together, they document how Oculis reports clinical progress, regulatory designations such as Breakthrough Therapy and Orphan Drug status for Privosegtor, and its capital structure.
On Stock Titan, investors can review these OCS filings alongside AI-powered summaries that explain the key points of each document, highlight material financing terms, and flag updates related to clinical programs or risk disclosures. The page also links to information on equity offerings, loan covenants, and warrant arrangements that may affect existing and prospective shareholders.
Oculis Holding AG announced equity financings totaling 5,432,098 ordinary shares at $20.25 per share, split between an underwritten sale of 4,691,358 shares and a registered direct sale of 740,740 shares. The underwriters also have a 30‑day option to purchase up to 703,703 additional shares at the same price.
Gross proceeds are expected to be approximately $110.0 million, or $124.2 million if the option is exercised in full. The closings are expected on or about November 3, 2025, subject to customary closing conditions. The company states that net proceeds, together with existing cash, cash equivalents and short‑term investments, are expected to fund operations to late 2028. The offerings were made under an effective Form F‑3 shelf registration.
Oculis Holding AG suspended and terminated its at-the-market prospectus that permitted sales of up to $100 million of ordinary shares under its May 8, 2024 sales agreement with Leerink Partners. As of this report, no shares were sold under the ATM prospectus. The underlying sales agreement remains in effect, and any future sales would require a new prospectus, prospectus supplement or registration statement.
Oculis Holding AG (OCS) filed a Form 144 reporting a proposed sale of 7,460 common shares, with an aggregate market value of $148,230.20, to be sold on 10/09/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filer reports the shares were acquired and paid for on 10/09/2025 through an exercise of stock options and that payment was made in cash. The filing notes 43,662,402 shares outstanding and states there were no sales in the past three months by the same person. The notice includes the standard signature representation about no undisclosed material adverse information.
Oculis Holding AG (OCS) announced initiation of the PIONEER clinical program for Privosegtor, a candidate to treat acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION). The program comprises three concurrent pivotal trials: PIONEER-1 beginning in Q4 2025 for AON, PIONEER-2 in the first half of 2026 measuring low-contrast visual acuity at 3 months, and PIONEER-3 in mid-2026 for NAION. PIONEER-2 will mirror dosing and enrollment from the positive Phase 2 ACUITY trial. Running the trials together is expected to create operational synergies, cost efficiencies, and accelerate timelines. The filing references accompanying press materials dated October 6, 2025.
Oculis Holding AG filing reports a proposed sale of 25,000 common shares through UBS Financial Services on 09/23/2025, with an aggregate market value of $442,500 based on the notice. The filing shows 43,662,402 shares outstanding. The shares were acquired on 03/02/2023 as issuance of earnout shares from the issuer and fully paid on that date. The filer reports no sales of the issuer's securities in the past three months and includes the standard representation that the seller is unaware of any undisclosed material adverse information.
Oculis Holding AG filed a Form 6-K to furnish its unaudited financial information for the three and six month periods ended June 30, 2025. The submission points investors to attached interim condensed consolidated financial statements and a Management’s Discussion and Analysis that explain the company’s financial condition and operating results over this mid‑year period.
The company also attached a related press release dated August 21, 2025. The financial statements and MD&A are incorporated by reference into existing Form S-8 and Form F-3 registration statements, linking these updated results to Oculis Holding’s ongoing equity compensation and potential securities offerings.